CompoAtlas

Complete Essentials Daily Pack for Men

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Zinc

Quelle : Citrate de zinc

3,75 mgNicht berechnet
Zinc

Quelle : Produit de chélation de zinc et de protéine végétale hydrolysée (PVH)

3,75 mgNicht berechnet
Zinc

Quelle : Oxyde de zinc

3,75 mgNicht berechnet
Potassium

Quelle : Citrate de potassium

12,5 mgNicht berechnet
2,5-Cyclohexadiène-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-décaméthyl-2,6,10,14,18,22,26,30,34,38-tétracontadécaényl]-5,6-diméthoxy-3-méthyl50 mgNicht berechnet
(2-Hydroxyethyl)trimethylammonium

Quelle : Bitartrate de choline

1,25 mgNicht berechnet
(2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one

Quelle : Citrus sinensis - fruit

150 mcgNicht berechnet
(2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one

Quelle : Citrus limon - Fruit

150 mcgNicht berechnet
Vitamine C

Quelle : Ascorbate de calcium

520 mgNicht berechnet
Vitamine C

Quelle : Ascorbate de magnésium

520 mgNicht berechnet
Vitamine C

Quelle : Ascorbate de sodium

520 mgNicht berechnet
Vitis vinifera

Quelle : Vitis vinifera - Graine

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 20 mg

5 mgNicht berechnet
3,3',4',5,7-pentahydroxyflavone

Quelle : Quercétine dihydraté

20 mgNicht berechnet
Linum usitatissimum

Quelle : Linum usitatissimum - Graine

30 mgNicht berechnet
(E)-5-(p-hydroxystyryl)resorcinol

Quelle : Polygonum cuspidatum - racine

25 mgNicht berechnet
Borago officinalis

Quelle : Borago officinalis

Stärke : 0 22% / 4.4 mg GLA (gamma linolenic acid)

20 mgNicht berechnet
Borago officinalis

Quelle : Huile de graines

Stärke : 0 22% / 4.4 mg GLA (gamma linolenic acid)

20 mgNicht berechnet
Curcuma longa

Quelle : Curcuma longa - rhizome

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 2 mg

0,5 mgNicht berechnet
Punica granatum

Quelle : Punica granatum, Fruit

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 8 mg

2 mgNicht berechnet
Bêta-carotène tout trans

Quelle : bêta-carotène

750 mcgNicht berechnet
Vitamine C

Quelle : Ascorbate de sodium

30 mgNicht berechnet
Vitamine C

Quelle : Ascorbate de calcium

30 mgNicht berechnet
Vitamine C

Quelle : Ascorbate de magnésium

30 mgNicht berechnet
Calcium

Quelle : Hydroxyapatite de calcium

200 mgNicht berechnet
Calcium

Quelle : Citrate de calcium

200 mgNicht berechnet
Calcium

Quelle : Gluconate de calcium

200 mgNicht berechnet
Calcium

Quelle : Carbonate de calcium

200 mgNicht berechnet
Vitamine D

Quelle : Cholécalciférol

1,25 mcgNicht berechnet
Vitamine E

Quelle : d-alpha tocophérol

Stärke : 7,5 UI

5 mg ATNicht berechnet
Vitamin K2

Quelle : Ménaquinones

20 mcgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus paradisi - Fruit

10 mgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus limon - Fruit

10 mgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus sinensis - fruit

10 mgNicht berechnet
Huile de poisson

Quelle : Huile du corps d'Anchois

Stärke : 300 mg EPA (eicosapentaenoic acid)

1.000 mgNicht berechnet
Huile de poisson

Quelle : Huile du corps de Sardine

Stärke : 300 mg EPA (eicosapentaenoic acid)

1.000 mgNicht berechnet
Huile de poisson

Quelle : Huile du corps d'Anchois

Stärke : 240 mg DHA (docosahexaenoic acid)

Nicht angegebenNicht berechnet
Huile de poisson

Quelle : Huile du corps de Sardine

Stärke : 240 mg DHA (docosahexaenoic acid)

Nicht angegebenNicht berechnet
Huile de poisson

Quelle : Huile du corps d'Anchois

Stärke : 60 mg Other omega fatty acids

Nicht angegebenNicht berechnet
Huile de poisson

Quelle : Huile du corps de Sardine

Stärke : 60 mg Other omega fatty acids

Nicht angegebenNicht berechnet
Punica granatum

Quelle : Punica granatum

50 mgNicht berechnet
Punica granatum

Quelle : Huile de graines

50 mgNicht berechnet
Oenothera biennis

Quelle : Oenothera biennis - huile de graine

Stärke : 0 9% / 1.8 mg GLA (gamma linolenic acid)

20 mgNicht berechnet
Linum usitatissimum

Quelle : Huile de graines

20 mgNicht berechnet
Linum usitatissimum

Quelle : Linum usitatissimum

20 mgNicht berechnet
Vitamine E

Quelle : d-alpha tocophérol

Stärke : 5 UI

3,35 mg ATNicht berechnet
Vitamine D

Quelle : Cholécalciférol

Stärke : 400 UI

10 mcgNicht berechnet
Vanadium

Quelle : Produit de chélation de vanadium et de PVH

1,25 mcgNicht berechnet
Thiamine

Quelle : Chlorhydrate de thiamine

1,875 mgNicht berechnet
Riboflavine

Quelle : Riboflavine

2,125 mgNicht berechnet
Niacinamide

Quelle : Niacinamide

5 mgNicht berechnet
Vitamine B6

Quelle : Chlorhydrate de pyridoxine

2,5 mgNicht berechnet
Folate

Quelle : Acide folique

150 mcgNicht berechnet
Vitamine B12

Quelle : Cyanocobalamine

3,75 mcgNicht berechnet
Biotine

Quelle : Biotine

75 mcgNicht berechnet
Acide pantothénique

Quelle : D-Pantothénate de calcium

2,5 mgNicht berechnet
Iode

Quelle : Varech

50 mcgNicht berechnet
Iode

Quelle : Iodure de potassium

50 mcgNicht berechnet
Magnésium

Quelle : Oxyde de magnésium

50 mgNicht berechnet
Magnésium

Quelle : Produit de chélation de magnésium et de protéine végétale hydrolysée (PVH)

50 mgNicht berechnet
Magnésium

Quelle : Citrate de magnésium

50 mgNicht berechnet
Sélénium

Quelle : Produit de chélation de sélénium et de protéine végétale hydrolysée (PVH)

25 mcgNicht berechnet
Cuivre

Quelle : Copper hydrolyzed vegetable protein (HVP) chelate

500 mcgNicht berechnet
Manganèse

Quelle : Produit de chélation de manganèse et de PVH

0,5 mgNicht berechnet
Chrome

Quelle : Produit de chélation de chrome (III) et de protéine végétale hydrolysée (PVH)

50 mcgNicht berechnet
Molybdène

Quelle : Produit de chélation de molybdène et de protéine végétale hydrolysée (PVH)

18,75 mcgNicht berechnet
Boron

Quelle : Citrate de bore

125 mcgNicht berechnet
Vitis vinifera

Quelle : Vitis vinifera - Graine

Stärke : 80 % Oligomeric proanthocyanidins

0,5 mgNicht berechnet
Camellia sinensis

Quelle : Camellia sinensis - feuille

Stärke : 36 % Catechins

5 mgNicht berechnet
Camellia sinensis

Quelle : Camellia sinensis - feuille

Stärke : 8 % Caffeine

Nicht angegebenNicht berechnet
Acide DL-alpha lipoÏque

Quelle : Acide DL-alpha-lipoÏque

5 mgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus sinensis - Écorce de fruit

200 mcgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus reticulata - Pelure (fruit)

200 mcgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus paradisi - Pelure (fruit)

200 mcgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus limon - Pelure (fruit)

200 mcgNicht berechnet
Bioflavonoïdes d'agrumes

Quelle : Citrus aurantiifolia - Pelure (fruit)

200 mcgNicht berechnet
3,3',4',5,7-Pentahydroxyflavone-3-rutinoside

Quelle : Sophora japonica, flower

2 mgNicht berechnet
Silybum marianum

Quelle : Silybum marianum - Graine

Stärke : 80 % Silymarin

2 mgNicht berechnet
Acide L-alpha-acétamido-bêta-mercaptopropionique

Quelle : L-alpha-Acetamido-beta-mercaptopropionic acid

2 mgNicht berechnet
Serenoa repens

Quelle : Serenoa repens - fruit

25 mgNicht berechnet
Stérols végétaux libres

Quelle : Glycine max - Graine

Stärke : 40 % Beta sitosterol

7,5 mgNicht berechnet
psi,psi-carotène

Quelle : Blakeslea trispora

1 mgNicht berechnet
Acide linoléique conjugué

Quelle : Free fatty acid form derived from natural safflower seed oil (Carthamus tinctorius)

325 mgNicht berechnet
Acide DL-alpha lipoÏque

Quelle : Acide DL-alpha-lipoÏque

0,5 mgNicht berechnet
Lycium chinense

Quelle : Lycium chinense - fruit

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 2 mg

0,5 mgNicht berechnet
Vitis vinifera

Quelle : Vitis vinifera - Fruit

0,5 mgNicht berechnet
Mélange de concentré de tocophérol

Quelle : Elaeis guineensis - Fruit

5,3 mgNicht berechnet
Withania somnifera

Quelle : Withania somnifera - racine

Stärke : 15 % Withanaloids

0,5 mgNicht berechnet
Concentré de tocotriénol

Quelle : Elaeis guineensis - Fruit

20 mgNicht berechnet
Punica granatum

Quelle : Punica granatum, Fruit

Extraktionsverhältnis : 4:1

Trockenpflanzenäquivalent : 2 mg

0,5 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Gélatine, Mélange de concentré de tocophérols, Hypromellose, Extrait de Medicago Sativa (Luzerne), Dioxyde de silicium, Extrait de romarin, Lécithine, Carbonate de calcium, Bicarbonate de sodium, Cire de Carnauba, Eau purifiée, Monoglycerides, Glycérine, Caramel, Palmitate d'ascorbyle, Saveur de citron, Croscarmellose sodium, Huile de tournesol, Betterave rouge, Hydroxypropylcellulose, Cellulose microcristalline, Saveur de lime, Stéarate de magnésium

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultes de sexe masculinNon précisée2 pack1 Tous les jours

In Kanada zugelassene Verwendungen

Source of vitamin A for the maintenance of good health. Source of vitamin A to help maintain eyesight, skin, membranes and immune function. Source of vitamin A to help in the development and maintenance of night vision. Source of vitamin A to help in the development and maintenance of bones and teeth. Helps the body to metabolize carbohydrates, fats and proteins. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps to produce and repair connective tissue. Helps in tissue formation. Helps in connective tissue formation. Helps in wound healing. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may reduce the risk of developing osteoporosis. Helps in the absorption and use of calcium and phosphorus. Helps normal growth and development. Helps to form red blood cells. Helps in the function of the thyroid gland. Helps to maintain proper muscle function. Helps to maintain healthy skin. Helps to maintain immune function. Provides support for healthy glucose metabolism. Source of antioxidants for the maintenance of good health. An antioxidant. An antioxidant for the maintenance of good health. A factor in the maintenance of good health. Helps to prevent vitamin C, vitamin E, vitamin B6, vitamin B12, thiamine, riboflavin, niacin, folate, biotin, pantothenic acid, iodine, zinc, selenium, copper, chromium, and molybdenum deficiencies. Source of omega-3 fatty acids, EPA, and DHA for the maintenance of good health. Helps support cognitive health and/or brain function. Helps maintain/support cardiovascular health. Helps to reduce serum triglycerides/ triacylglycerols. Helps to prevent vitamin D deficiency.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Consult a health care practitioner prior to use if you have been diagnosed with estrogen-dependant cancer, if you are taking blood pressure medication, or if you are taking other medications (i.e. drugs or natural health products), have a kidney, or have cystinuria, and/or have an iron deficiency, or if you are taking blood thinners. Consult a healthcare practitioner prior to use if you have gallstones, stomach ulcers, excess stomach acid, or if you are taking antiplatelet medication or cardiac glycosides such as digitalis/digoxin. If you have a liver disorder, consult a health care practitioner prior to use. Stop use if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner. Consult a health care practitioner prior to use if you are taking antidepressant medications. For Adult use only. If you are taking prescription medication, consult a healthcare practitioner prior to use as resveratrol may alter the effectiveness of these medications. Consult a health care practitioner for prolonged use, or if symptoms persist or worsen. Consult a health care practitioner prior to use if you are obese or have cardiovascular disease (CVD) risk factors (e.g. high blood pressure, high cholesterol and/or triglycerides).

Originaltext auf Englisch.

Known Adverse Reactions : Some people may experience gastrointestinal upset. Hypersensitivity, such as allergy, has been known to occur; in which case, discontinue use. Rare, unpredictable cases of liver injury associated with green tea extract-containing products have been reported (in Canada and internationally).

Originaltext auf Englisch.

Contra-Indications : Do not use if you are pregnant or breastfeeding or if you have a bile duct obstruction. Consumption with alcohol, other drugs, or natural health products with sedative properties is not recommended. If you are taking antibiotics, do not use this product. If you are taking nitroglycerin, do not use this product. Do not use if you have CVD, diabetes, metabolic syndrome or insulin resistance.

Originaltext auf Englisch.

Produktdaten

Inhaber
Isagenix Canada ULC
NPN oder DIN-HM
80072629
Status
Aktive Lizenz
Lizenzdatum
21. September 2016
Überarbeitungsdatum
21. Oktober 2016
Form
Comprimé
Verabreichungsweg
Orale
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80072629

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Linum usitatissimum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    FLAXSEED - LINUM USITATISSIMUM

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Gilt für Produkte: providing 5 g or more of flaxseed per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).

    Von Health Canada zitierte Quellen (1)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).

    Von Health Canada zitierte Quellen (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Anwendungsbedingung: Laxative; Promotion of bowel movement; Constipation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    Von Health Canada zitierte Quellen (2)
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
    • Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.

    Gegenanzeigen

    Gilt für Produkte: providing 5 g or more of flaxseed per day.

    Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).

    Von Health Canada zitierte Quellen (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).

    Von Health Canada zitierte Quellen (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).

    Von Health Canada zitierte Quellen (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.

    Monografie von Health Canada vom 26. Juli 2024

  • Borago officinalis
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen
  • Curcuma longa
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    TURMERIC - CURCUMA LONGA - Oral

    Art der Anwendung: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Von Health Canada zitierte Quellen (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Von Health Canada zitierte Quellen (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Anwendungsbedingung: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 26. September 2025

    Turmeric -CURCUMA LONGA - Topical

    Vorsichtsmaßnahmen und Warnhinweise

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Gegenanzeigen

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografie von Health Canada vom 28. Februar 2025

  • Punica granatum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen
  • Vitamine D
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    VITAMIN D (>1,000 - 2,500 IU)

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Von Health Canada zitierte Quellen (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Gilt für Produkte: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gilt für Produkte: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gegenanzeigen

    Anwendungsbedingung: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografie von Health Canada vom 26. Juni 2026

  • Huile de poisson
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    FISH OIL

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: Pain of rheumatoid arthritis.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Anwendungsbedingung: Healthy mood balance.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.

    Monografie von Health Canada vom 25. September 2026

  • Oenothera biennis
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen
  • Silybum marianum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    MILK THISTLE - SILYBUM MARIANUM

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).

    Von Health Canada zitierte Quellen (2)
    • Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
    • Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).

    Monografie von Health Canada vom 26. Juni 2026

  • Serenoa repens
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    SAW PALMETTO – SERENOA REPENS

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (2)
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.

    Anwendungsbedingung: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    Von Health Canada zitierte Quellen (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Gegenanzeigen

    Anwendungsbedingung: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    Von Health Canada zitierte Quellen (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Monografie von Health Canada vom 19. Dezember 2025

  • Acide linoléique conjugué
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CONJUGATED LINOLEIC ACID

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are obese or have cardiovascular disease (CVD) risk factors (Tholstrup et al. 2008; Gaullier et al. 2007; Steck et al. 2007; Larsen et al. 2006; Taylor et al. 2006; Gaullier et al. 2005; Smedman et al. 2005; Gaullier et al. 2004; Basu et al. 2000a,b).

    Von Health Canada zitierte Quellen (9)
    • Basu S, Risérus U, Turpeinen A, Vessby B. 2000a. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science 99(6):511-516.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. The American Journal of Clinical Nutrition 79:1118-1125.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. The Journal of Nutrition 135(4):778-784.
    • Larsen TM, Toubro S, Gundmensen O, Astrup A. 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat gain. The American Journal of Clinical Nutrition 83(3):606-612.
    • Smedman A, Basu S, Jovinge S, Fredrikson GN, Vessby B. 2005. Conjugated linoleic acid increased C-reactive protein in human subjects. British Journal of Nutrition 94(5):791-795.
    • Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, Albright CD, Thuillier P. 2007. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. The Journal of Nutrition 137(5):1188-1193.
    • Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. 2006. Conjugated linoleic acid impairs endothelial function. Arteriosclerosis, Thrombosis, and Vascular Biology 26(2):307-312.
    • Tholstrup T, Raff M, Straarup EM, Lund P, Basu S, Bruun JM. 2008. An oil mixture with trans-10, cis-12 conjugated linoleic acid increases markers of inflammation and in vivo lipid peroxidation compared with cis-9, trans-11 conjugated linoleic acid in postmenopausal women. The Journal of Nutrition 138(8):1445-1451.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if your goal is to achieve weight loss.

    Gegenanzeigen

    Do not use if you are pregnant (HC 2010).

    Von Health Canada zitierte Quellen (2)
    • HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
    • SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf

    Do not use if you have cardiovascular disease (CVD), diabetes, metabolic syndrome or insulin resistance (Tholstrup et al. 2008; Gaullier et al. 2007; Steck et al. 2007; Larsen et al. 2006; Taylor et al. 2006; Gaullier et al. 2005; Smedman et al. 2005; Gaullier et al. 2004; Moloney et al. 2004; Basu et al. 2000a,b).

    Von Health Canada zitierte Quellen (10)
    • Basu S, Risérus U, Turpeinen A, Vessby B. 2000a. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science 99(6):511-516.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. The American Journal of Clinical Nutrition 79:1118-1125.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. The Journal of Nutrition 135(4):778-784.
    • Larsen TM, Toubro S, Gundmensen O, Astrup A. 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat gain. The American Journal of Clinical Nutrition 83(3):606-612.
    • Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. 2004. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. The American Journal of Clinical Nutrition 80(4):887-895.
    • Smedman A, Basu S, Jovinge S, Fredrikson GN, Vessby B. 2005. Conjugated linoleic acid increased C-reactive protein in human subjects. British Journal of Nutrition 94(5):791-795.
    • Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, Albright CD, Thuillier P. 2007. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. The Journal of Nutrition 137(5):1188-1193.
    • Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. 2006. Conjugated linoleic acid impairs endothelial function. Arteriosclerosis, Thrombosis, and Vascular Biology 26(2):307-312.
    • Tholstrup T, Raff M, Straarup EM, Lund P, Basu S, Bruun JM. 2008. An oil mixture with trans-10, cis-12 conjugated linoleic acid increases markers of inflammation and in vivo lipid peroxidation compared with cis-9, trans-11 conjugated linoleic acid in postmenopausal women. The Journal of Nutrition 138(8):1445-1451.

    Bekannte Nebenwirkungen

    When using this product you may experience gastrointestinal discomfort/disturbances (Gaullier et al. 2007; Pinkoski et al. 2006; Berven et al. 2000; Blankson et al. 2000).

    Von Health Canada zitierte Quellen (4)
    • Berven G, Bye A, Hals O, Blankson H, Fagertun H, Thom E, Wadstein J, Gudmundsen O. 2000. Safety of conjugated linoleic acid (CLA) in overweight and obese human volunteers. European Journal of Lipid Science and Technology 102(7):455-462.
    • Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. 2000. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. The Journal of Nutrition 130(12):2943-2948.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, Farthing JP, Zello GA. 2006. The effects of conjugated linoleic acid supplementation during resistance training. Medicine and Science in Sports and Exercise 38(2):339-348.

    Monografie von Health Canada vom 10. Januar 2025

  • Withania somnifera
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Von Health Canada zitierte Quellen (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Monografie von Health Canada vom 28. Februar 2025

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2016. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile